QUEBEC CITY, April 30, 2015 /PRNewswire/ - DiagnoCure Inc.
(TSX: CUR) (OTCQX: DGCRF) (the "Corporation") today announced that
its shareholders have approved all resolutions presented to them in
the Management Proxy Circular dated March 5,
2015 and put forth for vote during the shareholders meeting
held today in Montreal.
Shareholders re-elected Dr. Yves
Fradet, Dr. Louise Proulx,
Mr. Andrew Sheldon, Dr. Jacques Simoneau, and Dr. Vincent R.
Zurawski as directors of the Corporation.
This year, 57.85% of the shares were voted and the results for
the nominees as directors are as follows:
|
Nominees
|
Shares
For
|
For
(%)
|
Shares
Withheld
|
Withheld
(%)
|
Non-votes
|
|
Yves
Fradet
|
20,334,619
|
93.34
|
1,449,871
|
6.66
|
3,113,479
|
|
Louise
Proulx
|
20,336,619
|
93.35
|
1,447,871
|
6.65
|
3,113,479
|
|
Andrew J.
Sheldon
|
20,336,119
|
93.35
|
1,448,371
|
6.65
|
3,113,479
|
|
Jacques
Simoneau
|
20,396,619
|
93.62
|
1,387,871
|
6.38
|
3,113,479
|
|
Vincent R.
Zurawski
|
21,631,619
|
99.30
|
152,871
|
0.70
|
3,113,479
|
Shareholders also reappointed Ernst & Young as auditor of
the Corporation and the result is as follows:
|
Shares
For
|
For
(%)
|
Shares
Withheld
|
Withheld
(%)
|
Non-vote
|
|
Auditor
appointment
|
24,860,855
|
99.85
|
37,114
|
0.15
|
0
|
The presentation given by Dr. Yves
Fradet and Mr. Richard
Bordeleau after completion of the formal business portion of
the meeting today is available on DiagnoCure's website at
www.diagnocure.com through a link on the Investors page;
Presentations.
"The Board of directors greatly appreciates the strong support
of our shareholders, which was manifested in this vote and which
will be of great value as we proceed with the ongoing discussions
to improve royalties from PCA3, to out-license our assets and
pursue potential strategic merger activities", stated Dr.
Yves Fradet, Chairman of the Board
and President and Chief Medical Officer of the Corporation.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences
corporation that develops and provides molecular and genomic tests
to support effective clinical decisions enabling personalized
medicine in oncology. Previstage® GCC and the Corporation new
multimarker prostate cancer test are currently available for
licensing. The Corporation has granted a worldwide exclusive
license on the diagnostic applications of PCA3 for the development
and commercialization of a prostate cancer test which is now
commercialized in Europe under CE
mark and approved for commercialization in Canada and the
United States. For more information, please visit
www.diagnocure.com.
Forwardlooking statements
This release may contain forwardlooking statements that involve
known and unknown risks, uncertainties and assumptions that may
cause actual results to differ materially from those expected.
Forward-looking statements can be identified by the use of the
conditional or forward-looking terminology such as "anticipates",
"assumes", "believes", "estimates", "expects", "intend", "may",
"plans", "projects", "should", "will", or the negative thereof or
other variations thereon. Forward-looking statements also include
any other statements that do not refer to historical facts. All
such forward-looking statements are made pursuant to the
"safe-harbour" provisions of applicable Canadian securities laws.
By their very nature, forwardlooking statements are based on
expectations and assumptions and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. Forward-looking statements are presented for
the purpose of assisting investors and others in understanding
certain key elements of the Corporation's current objectives,
strategic priorities, expectations and plans, and in obtaining a
better understanding of the Corporation's business and anticipated
operating environment. Readers are cautioned that such information
may not be appropriate for other purposes and that they should not
place undue reliance on these forwardlooking statements. For
instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PCP Risk Score are based on
management expectations and such outcome may vary materially
depending on global political and economic conditions, dependence
on collaboration partners, uncertainty of healthcare reimbursement,
and marketing and distribution challenges. In addition, the reader
is referred to the applicable general risks and uncertainties
described in DiagnoCure's most recent Annual Information Form under
the heading "Risk Factors". DiagnoCure undertakes no obligation to
publicly update or revise any forwardlooking statements contained
herein unless required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.